Skip to main content

Table 5 Change from baseline in MIDAS response by baseline MIDAS disability severity (<21 vs. ≥21)

From: Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study

  MIDAS total < 21 at baselineMIDAS total ≥ 21 at baseline
Lasmiditan 100 mg (n = 418)Lasmiditan 200 mg (n = 465)Lasmiditan 100 mg (n = 554)Lasmiditan 200 mg(n = 598)
 LS mean% change in meanLS mean% change in meanLS mean% change in meanLS mean% change in mean
MIDAS TotalBaseline, mean13.813.841.140.7
Month 3−0.6−4.2−1.7**−12.5−13.3**−32.3− 11.3**−27.9
Month 6−1.9**−13.9−2.5**− 18.3− 16.1**− 39.1− 14.9**− 36.6
Month 9− 2.6**− 18.9− 3.9**−28.0− 17.8**− 43.3− 15.3**− 37.7
Month 12− 4.1**− 29.7− 4.2**− 30.4− 19.3**− 47.0− 19.5**− 47.8
AbsenteesimBaseline, mean1.471.674.374.38
Month 3−0.1−5.4− 0.4**−22.2−1.1**− 24.0− 1.2**− 26.3
Month 6− 0.1−6.1− 0.2− 12.0− 1.5**−35.2− 1.6**− 35.4
Month 9− 0.3*−17.7− 0.3*−19.8− 1.6**−36.8−1.5**− 35.2
Month 12− 0.2−10.2− 0.4*− 22.2− 1.7**−39.4− 2.0**− 45.2
PresenteeismBaseline, mean2.773.029.008.70
Month 3−0.02− 0.7− 0.2−7.6−2.7**− 29.9− 2.3**− 26.0
Month 6− 0.1−4.7− 0.3−9.6−3.6**− 39.7− 3.1**− 35.6
Month 9− 0.3− 10.5− 0.8**−24.8−3.9**− 43.1− 2.8**−31.8
Month 12− 0.6*− 23.1− 0.6*− 20.5− 4.1**− 45.4−3.9**− 44.3
Headache daysaBaseline, mean11.0510.9218.8919.14
Month 3−2.7**−24.7− 2.1**−19.5−4.1**− 21.7−5.2**−27.4
Month 6−2.8**−25.0− 2.2**−20.4− 5.8**−30.8− 5.5**−28.9
Month 9−3.7**−33.6− 3.4**− 31.1−6.4**− 34.1− 7.6**−39.9
Month 12−4.6**−41.2−3.3**−30.0−6.6**− 34.9−8.4**− 43.9
Average headache pain intensityaBaseline, mean7.327.147.467.49
Month 3−0.4*−4.9− 0.4**−5.9− 0.4**− 5.8− 0.4**− 5.6
Month 6−0.7**−10.1− 0.6**−8.0−0.6**− 8.3− 0.7**−9.9
Month 9−0.8**− 10.4−1.0**− 14.1− 0.8**−10.3− 0.8**− 10.0
Month 12−1.0**− 13.8−1.2**− 16.7−1.2**− 16.1−1.3**− 17.0
  1. *p < .05; **p < .001. aNot included in MIDAS total score. Abbreviations: BL = baseline; LS mean = least squares mean; n = number of patients in subgroup
\